Lorazepam
Metastasis
Merck Sharp & Dohme LLCSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PAMIDRONIC ACID Ottawa Hospital Research Institute | Phase 4 | BB |
TAMOXIFEN National Cancer Center, Korea | Phase 3 | BB |
Palbociclib Eli Lilly and Company | Phase 3 | BB |
Abiraterone Acetate Merck Sharp & Dohme LLC | Phase 3 | BB |
Sorafenib Wake Forest University Health Sciences | Phase 4 | BB |
View all 46 →
Same molecule, other indications
Lorazepam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →